
Serena Pillozzi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1850454/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Targeting Ion Channels in Cancer: A Novel Frontier in Antineoplastic Therapy. Current Medicinal Chemistry, 2009, 16, 66-93.	2.4	269
2	HERG potassium channels are constitutively expressed in primary human acute myeloid leukemias and regulate cell proliferation of normal and leukemic hemopoietic progenitors. Leukemia, 2002, 16, 1791-1798.	7.2	177
3	VEGFR-1 (FLT-1), β1 integrin, and hERG K+ channel for a macromolecular signaling complex in acute myeloid leukemia: role in cell migration and clinical outcome. Blood, 2007, 110, 1238-1250.	1.4	165
4	Human ether-a-go-go-related Gene 1 Channels Are Physically Linked to $\hat{1}^21$ Integrins and Modulate Adhesion-dependent Signaling. Molecular Biology of the Cell, 2005, 16, 2972-2983.	2.1	147
5	Chemotherapy resistance in acute lymphoblastic leukemia requires hERG1 channels and is overcome by hERG1 blockers. Blood, 2011, 117, 902-914.	1.4	119
6	HERG K+ Channels Activation during β1Integrin-mediated Adhesion to Fibronectin Induces an Up-regulation of αvβ3 Integrin in the Preosteoclastic Leukemia Cell Line FLG 29.1. Journal of Biological Chemistry, 2001, 276, 4923-4931.	3.4	83
7	Insights into the Structure/Function of Hepatocyte Growth Factor/Scatter Factor from Studies with Individual Domains. Journal of Molecular Biology, 2007, 367, 395-408.	4.2	80
8	hERG1 channels modulate integrin signaling to trigger angiogenesis and tumor progression in colorectal cancer. Scientific Reports, 2013, 3, 3308.	3.3	75
9	Replacement of the Thiosugar of Auranofin with Iodide Enhances the Anticancer Potency in a Mouse Model of Ovarian Cancer. ACS Medicinal Chemistry Letters, 2019, 10, 656-660.	2.8	64
10	The combined activation of KCa3.1 and inhibition of Kv11.1/hERG1 currents contribute to overcome Cisplatin resistance in colorectal cancer cells. British Journal of Cancer, 2018, 118, 200-212.	6.4	58
11	Glutamine depletion by crisantaspase hinders the growth of human hepatocellular carcinoma xenografts. British Journal of Cancer, 2014, 111, 1159-1167.	6.4	55
12	Identification of a Posttranslational Mechanism for the Regulation of hERG1 K ⁺ Channel Expression and hERG1 Current Density in Tumor Cells. Molecular and Cellular Biology, 2008, 28, 5043-5060.	2.3	54
13	Targeting Ion Channels in Leukemias: A New Challenge for Treatment. Current Medicinal Chemistry, 2012, 19, 683-696.	2.4	54
14	hERG1 Channels Regulate VEGF-A Secretion in Human Gastric Cancer: Clinicopathological Correlations and Therapeutical Implications. Clinical Cancer Research, 2014, 20, 1502-1512.	7.0	54
15	Design, synthesis and characterisation of new chimeric ruthenium(<scp>ii</scp>)–gold(<scp>i</scp>) complexes as improved cytotoxic agents. Dalton Transactions, 2015, 44, 11067-11076.	3.3	52
16	The conformational state of hERG1 channels determines integrin association, downstream signaling, and cancer progression. Science Signaling, 2017, 10, .	3.6	49
17	cis-Pt I ₂ (NH ₃) ₂ : a reappraisal. Dalton Transactions, 2015, 44, 14896-14905.	3.3	45
18	The Increase of Endothelial Progenitor Cells in the Peripheral Blood: A New Parameter for Detecting Onset and Severity of Sepsis. International Journal of Immunopathology and Pharmacology, 2008, 21, 697-705.	2.1	43

#	Article	IF	CITATIONS
19	Immune Checkpoint Inhibitors in the Treatment of Renal Cancer: Current State and Future Perspective. International Journal of Molecular Sciences, 2020, 21, 4691.	4.1	40
20	Physical and Functional Interaction between Integrins and hERG1 Channels in Cancer Cells. Advances in Experimental Medicine and Biology, 2010, 674, 55-67.	1.6	40
21	New Insights into the Regulation of Ion Channels by Integrins. International Review of Cell and Molecular Biology, 2010, 279, 135-190.	3.2	38
22	Tumor-selective peptide-carrier delivery of Paclitaxel increases in vivo activity of the drug. Scientific Reports, 2015, 5, 17736.	3.3	38
23	Association between Immune Related Adverse Events and Outcome in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors. Cancers, 2021, 13, 860.	3.7	37
24	Ptl ₂ (DACH), the iodido analogue of oxaliplatin as a candidate for colorectal cancer treatment: chemical and biological features. Dalton Transactions, 2017, 46, 3311-3317.	3.3	35
25	NAMI-A is highly cytotoxic toward leukaemia cell lines: evidence of inhibition of KCa 3.1 channels. Dalton Transactions, 2014, 43, 12150-12155.	3.3	34
26	Ion Channels in Hematopoietic and Mesenchymal Stem Cells. Stem Cells International, 2012, 2012, 1-9.	2.5	33
27	HERG K ⁺ Channels and β1 Integrins Interact through the Assembly of a Macromolecular Complex. Annals of the New York Academy of Sciences, 2002, 973, 559-561.	3.8	29
28	Developmentally regulated expression of the mouse homologues of the potassium channel encoding genes m-erg1, m-erg2 and m-erg3. Gene Expression Patterns, 2003, 3, 767-776.	0.8	29
29	New gold carbene complexes as candidate anticancer agents. BioMetals, 2016, 29, 905-911.	4.1	29
30	New Pyrimido-Indole Compound CD-160130 Preferentially Inhibits the K _V 11.1B Isoform and Produces Antileukemic Effects without Cardiotoxicity. Molecular Pharmacology, 2015, 87, 183-196.	2.3	26
31	Antiproliferative properties and biomolecular interactions of three Pd(II) and Pt(II) complexes. Journal of Inorganic Biochemistry, 2016, 165, 1-6.	3.5	26
32	hLH/hCG-receptor expression correlates with in vitro invasiveness in human primary endometrial cancer. Gynecologic Oncology, 2008, 111, 496-501.	1.4	25
33	Relationships between hepatic melanogenesis and respiratory conditions in the newt,Triturus carnifex. The Journal of Experimental Zoology, 2000, 287, 120-127.	1.4	23
34	Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA = 1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties. Journal of Inorganic Biochemistry, 2016, 160, 180-188.	3.5	23
35	Electrochemical and PEC platforms for miRNA and other epigenetic markers of cancer diseases: Recent updates. Electrochemistry Communications, 2021, 124, 106929.	4.7	23
36	Circulating tumour cells and cell-free DNA as a prognostic factor in metastatic colorectal cancer: the OMITERC prospective study. British Journal of Cancer, 2021, 125, 94-100.	6.4	23

#	Article	IF	CITATIONS
37	Association of Systemic Steroid Treatment and Outcome in Patients Treated with Immune Checkpoint Inhibitors: A Real-World Analysis. Molecules, 2021, 26, 5789.	3.8	23
38	VEGFR-1 (FLT-1), b1 Integrin and hERG K+ Channel Form a Macromolecular Signaling Complex in Acute Myeloid Leukemia Cells Blood, 2006, 108, 2366-2366.	1.4	22
39	Chasing the Target: New Phenomena of Resistance to Novel Selective RET Inhibitors in Lung Cancer. Updated Evidence and Future Perspectives. Cancers, 2021, 13, 1091.	3.7	21
40	Physical and functional interaction between integrins and hERG potassium channels. Biochemical Society Transactions, 2004, 32, 826-827.	3.4	20
41	The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma. Scientific Reports, 2019, 9, 8586.	3.3	20
42	Soft Tissue Sarcoma: An Insight on Biomarkers at Molecular, Metabolic and Cellular Level. Cancers, 2021, 13, 3044.	3.7	20
43	Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups. Leukemia, 2014, 28, 1352-1355.	7.2	18
44	Safety of Immune Checkpoint Inhibitors in Elderly Patients: An Observational Study. Current Oncology, 2021, 28, 3259-3267.	2.2	18
45	Hepatocyte Growth Factor Receptor c-MET Is Associated with FAS and When Activated Enhances Drug-induced Apoptosis in Pediatric B Acute Lymphoblastic Leukemia with TEL-AML1 Translocation. Journal of Biological Chemistry, 2007, 282, 29384-29393.	3.4	17
46	Irresponsiveness of two retinoblastoma cases to conservative therapy correlates with up- regulation of hERG1 channels and of the VEGF-A pathway. BMC Cancer, 2010, 10, 504.	2.6	17
47	Searching for protein binding sites from Molecular Dynamics simulations and paramagnetic fragment-based NMR studies. Biochimica Et Biophysica Acta - Proteins and Proteomics, 2014, 1844, 561-566.	2.3	17
48	Cisplatin and its dibromido analogue: a comparison of chemical and biological profiles. BioMetals, 2016, 29, 535-542.	4.1	13
49	Anticancer effects against colorectal cancer models of chloro(triethylphosphine)gold(I) encapsulated in PLGA–PEG nanoparticles. BioMetals, 2021, 34, 867-879.	4.1	13
50	Circulating Endothelial Progenitor Cells in Type 1 Diabetic Patients: Relation with Patients' Age and Disease Duration. Frontiers in Endocrinology, 2017, 8, 278.	3.5	12
51	Peptides and small molecules blocking the CXCR4/CXCL12 axis overcome bone marrow‑induced chemoresistance in acute leukemias. Oncology Reports, 2018, 41, 312-324.	2.6	12
52	Structural and solution chemistry, antiproliferative effects, and serum albumin binding of three pseudohalide derivatives of auranofin. BioMetals, 2019, 32, 939-948.	4.1	12
53	Transgenic mice overexpressing the LH receptor in the female reproductive system spontaneously develop endometrial tumour masses. Scientific Reports, 2021, 11, 8847.	3.3	12
54	Over-Expression of the LH Receptor Increases Distant Metastases in an Endometrial Cancer Mouse Model. Frontiers in Oncology, 2013, 3, 285.	2.8	11

#	Article	IF	CITATIONS
55	Macrolide antibiotics exert antileukemic effects by modulating the autophagic flux through inhibition of hERG1 potassium channels. Blood Cancer Journal, 2016, 6, e423-e423.	6.2	11
56	Pilot investigation of the mutation profile of PIK3CA/PTEN genes (PI3K pathway) in grade 3 endometrial cancer. Oncology Reports, 2018, 41, 1560-1574.	2.6	11
57	Eosinophil Count as Predictive Biomarker of Immune-Related Adverse Events (irAEs) in Immune Checkpoint Inhibitors (ICIs) Therapies in Oncological Patients. Immuno, 2021, 1, 253-263.	1.5	11
58	Engineering <scp>l</scp> -asparaginase for spontaneous formation of calcium phosphate bioinspired microreactors. Physical Chemistry Chemical Physics, 2018, 20, 12719-12726.	2.8	9
59	Ivosidenib in IDH1-mutated cholangiocarcinoma: Clinical evaluation and future directions. , 2022, 237, 108170.		9
60	Chlorido and bromido oxaliplatin analogues as potential agents for CRC treatment: Solution behavior, protein binding and cytotoxicity evaluation. Inorganica Chimica Acta, 2018, 470, 318-324.	2.4	8
61	Deregulation of Ion Channel and Transporter Encoding Genes in Pediatric Gliomas. Frontiers in Oncology, 2012, 2, 53.	2.8	7
62	Severe hypoxia selects hematopoietic progenitors with stem cell potential from primary Myelodysplastic syndrome bone marrow cell cultures. Oncotarget, 2018, 9, 10561-10571.	1.8	7
63	Luteinizing Hormone/Human Chorionic Gonadotropin Receptor Immunohistochemical Score Associated with Poor Prognosis in Endometrial Cancer Patients. BioMed Research International, 2018, 2018, 1-6.	1.9	6
64	Identification of a Gene Panel for Endometrioid Endometrial Cancer: a Possible Prognostic Value?. Reproductive Sciences, 2020, 27, 592-598.	2.5	6
65	Aflibercept Plus FOLFIRI as Second-Line Treatment for Metastatic Colorectal Cancer: A Single-Institution Real-Life Experience. Cancers, 2021, 13, 3863.	3.7	6
66	Absolute eosinophil count predicts clinical outcomes and toxicity in non-small cell lung cancer patients treated with immunotherapy. Cancer Treatment and Research Communications, 2022, 32, 100603.	1.7	6
67	Chip-Based and Wearable Tools for Isothermal Amplification and Electrochemical Analysis of Nucleic Acids. Chemosensors, 2022, 10, 278.	3.6	6
68	Potent in vitro antiproliferative properties for a triplatinum cluster toward triple negative breast cancer cells. Journal of Inorganic Biochemistry, 2016, 163, 318-322.	3.5	5
69	A Machine Learning Decision Support System (DSS) for Neuroendocrine Tumor Patients Treated with Somatostatin Analog (SSA) Therapy. Diagnostics, 2021, 11, 804.	2.6	5
70	Activity and Safety of NAB-FOLFIRI and NAB-FOLFOX as First-Line Treatment for metastatic Pancreatic Cancer (NabucCO Study). Current Oncology, 2021, 28, 1761-1772.	2.2	5
71	Somatostatin analogs in pregnant patients with neuroendocrine tumor. Anti-Cancer Drugs, 2020, 31, 1096-1098.	1.4	5
72	LH/hCG-Receptor Expression May Have a Negative Prognostic Value in Low-Risk Endometrial Cancer. Frontiers in Oncology, 2016, 6, 190.	2.8	3

#	Article	IF	CITATIONS
73	Circulating miRNome profiling data in Behçet's syndrome. Data in Brief, 2021, 38, 107435.	1.0	3
74	Data describing the effects of the Macrolide Antibiotic Clarithromycin on preclinical mouse models of Colorectal Cancer. Data in Brief, 2019, 26, 104406.	1.0	2
75	Mutational profile in circulating tumor DNA in a patient affected by low-risk endometrial cancer: predictable tool of relapse?. Anti-Cancer Drugs, 2020, 31, 1091-1095.	1.4	2
76	Expression and Role of hERG1 Channels in Pediatric Acute Lymphoblastic Leukemias: Shortcoming of Drug Resistance by hERG1 Channel Inhibitors in Stoma-Supported Leukaemia Cell Cultures In Vitro Blood, 2007, 110, 724-724.	1.4	2
77	Treatment with hERG1 K+ Channel Inhibitors Reduces Acute Myeloid Leukemia Cell Lines Engraftment into Nonobese Diabetic/Severe Combined Immunodeficient Mice and Prolongs Survival of Injected Mice Blood, 2007, 110, 877-877.	1.4	2
78	Detection of PIK3CA E545A mutation in circulating tumor DNA of a patient affected by uterine carcinosarcoma. Anti-Cancer Drugs, 2020, 31, 880-883.	1.4	1
79	c-Met Oncogene Enhances Fas-Mediated Apoptosis in B-ALL t(12;21) Cells Blood, 2005, 106, 858-858.	1.4	1
80	Potassium Channels as Novel Pharmacological Targets in Acute Myeloid Leukemia. Blood, 2008, 112, 4034-4034.	1.4	1
81	Overcoming Chemotherapy Resistance in Childhood Acute Lymphoblastic Leukemia by Targeting Ion Channels Blood, 2009, 114, 3085-3085.	1.4	1
82	Macrolide Antibiotics By Modulating the Autophagic Flux Exert an Antileukemic Effect through the Involvement of hERG1 Potassium Channel. Blood, 2016, 128, 3953-3953.	1.4	1
83	A Macromolecular Signaling Complex Formed by CXCR4, VLA4 and hERG1 K+ Channels Mediates Bone Marrow-Induced Chemo-Resistance in Childhood Acute Lymphoblastic Leukemias: Shortcoming Effects of hERG1 Channels Inhibitors Blood, 2008, 112, 1629-1629.	1.4	0
84	Role of the Ether-a-gò-gò-Related Gene 1B Isoform in Hematopoiesis. Blood, 2012, 120, 1222-1222.	1.4	0
85	Identification of Non-Cardiotoxic hERG1 Blockers to Overcome Chemoresistance in Acute Lymphoblastic Leukemias. Blood, 2012, 120, 1506-1506.	1.4	0
86	Drugâ€induced glutamine depletion hinders the growth of β―catenin mutated human liver cancer xenografts. FASEB Journal, 2013, 27, 387.9.	0.5	0
87	Hypoxia Increases Repopulating Ability of Myelodysplastic Syndrome Bone Marrow Cells. Blood, 2015, 126, 4753-4753.	1.4	0
88	ROS1 rearrangements are uncommon in biliary tract cancers. Oncology Letters, 2020, 20, 1-1.	1.8	0